Galectin Therapeutics Inc
$ 3.45
7.14%
07 Aug - close price
- Market Cap 347,931,000 USD
- Current Price $ 3.45
- High / Low $ 3.56 / 3.22
- Stock P/E N/A
- Book Value -2.01
- EPS -0.41
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.80 %
- ROE -37.28 %
- 52 Week High 7.13
- 52 Week Low 2.03
About
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The company is headquartered in Norcross, Georgia.
Analyst Target Price
$11.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-15 | 2026-03-31 | 2025-11-14 | 2025-08-14 | 2025-05-15 | 2025-03-31 | 2024-11-14 | 2024-08-13 | 2024-05-15 | 2024-03-29 | 2023-11-13 | 2023-08-14 |
| Reported EPS | -0.08 | -0.08 | -0.13 | -0.12 | -0.15 | -0.19 | -0.18 | -0.2 | -0.19 | -0.16 | -0.24 | -0.15 |
| Estimated EPS | -0.06 | -0.1 | -0.11 | -0.16 | -0.11 | -0.16 | -0.2 | -0.16 | -0.16 | -0.16 | -0.16 | -0.21 |
| Surprise | -0.02 | 0.02 | -0.02 | 0.04 | -0.04 | -0.03 | 0.02 | -0.04 | -0.03 | 0 | -0.08 | 0.06 |
| Surprise Percentage | -33.3333% | 20% | -18.1818% | 25% | -36.3636% | -18.75% | 10% | -25% | -18.75% | 0% | -50% | 28.5714% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.09 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GALT
2026-08-04 12:12:09
Richard E. Uihlein has converted approximately $105.8 million in debt owed by Galectin Therapeutics Inc. (GALT) into 34,376,167 shares of common stock. This transaction increases his beneficial ownership to 54,673,646 shares, representing about 49.30% of the outstanding common stock. Uihlein maintains sole voting and dispositive power over these shares, stating his investment is for investment purposes rather than to influence control of the company.
2026-08-04 12:12:08
Richard E. Uihlein, a director and over-10% holder of Galectin Therapeutics (GALT), converted Line of Credit Convertible Notes totaling over $100 million into 34,376,167 common shares at prices of $3.00 and $4.05 per share. This transaction significantly increased his indirect common stock holdings via the Richard E. Uihlein Stock Trust, while eliminating the convertible notes. The filing also notes holdings by the Ed Uihlein Family Foundation, where he shares voting power but has no pecuniary interest.
2026-08-04 12:12:08
Galectin Therapeutics announced that its Chairman, Richard E. Uihlein, converted $105.8 million in outstanding debt, including principal and accrued interest, into 34,376,167 shares of common stock. This conversion significantly strengthens the company's balance sheet by eliminating substantial debt and reflects Mr. Uihlein's continued confidence in Galectin's galectin-3 inhibitor platform and its mission to address MASH cirrhosis. A separate $10 million credit facility remains undrawn and available for future financing.
2026-07-31 03:41:24
This article provides a technical analysis of Galectin Therapeutics Inc (GALT), detailing its support, resistance levels, and various technical indicators. It presents a summary of buy, sell, and neutral signals from indicators like MACD, RSI, and moving averages, concluding with a neutral overall signal based on its analysis. The article also provides FAQs explaining fundamental technical analysis concepts.
2026-07-30 10:41:24
This page provides financial overview information for Galectin Therapeutics Inc. (NASDAQ: GALT). It details access to financial statements, statistics, dividends, earnings, and segment performance. The page is part of TradingView, which offers various market analysis tools and data.
2026-07-27 17:10:25
This article provides a brief overview of Galectin Therapeutics Inc (GALT)'s financial health, focusing on profitability and balance sheet analysis. It presents current stock price, market capitalization, and a prompt for more detailed financial and analysis information. The content also notes the absence of a P/E TTM ratio, implying a lack of profitability.
